SSSudhindran Surendran

Sudhindran Surendran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sudhindran Surendran has a total of 731 co-authors. Here are the top co-authors by number of shared publications:

  • Dinesh Balakrishnan

    Department of Gastrointestinal Surgery and Solid Organ Transplantation, Amrita Institute of Medical Sciences and Research Centre, Amrita University, Kochi, Kerala, India

    25 shared publications
  • Puneet Dhar

    Surgical Gastroenterology, All India Institute of Medical Sciences, Rishikesh, IND

    17 shared publications
  • Unnikrishnan Gopalakrishnan

    Department of Gastrointestinal Surgery and Solid Organ Transplantation, Amrita Institute of Medical Sciences and Research Centre, Amrita University, Kochi, Kerala, India

    14 shared publications
  • Shweta Mallick

    Department of Gastrointestinal Surgery and Solid Organ Transplantation, Amrita Institute of Medical Sciences and Research Centre, Amrita University, Kochi, Kerala, India

    13 shared publications
  • Ramachandran Narayana Menon

    GI Surgery, Amrita Institute of Medical Sciences & Research Centre, Kochi Coimbatore Tamil Nadu Amrita Vishwa Vidyapeetham

    10 shared publications
  • Krishnanunni Nair

    GI Surgery, Amrita Institute of Medical Sciences & Research Centre, Kochi Coimbatore Tamil Nadu Amrita Vishwa Vidyapeetham

    9 shared publications

Latest Publications

  • Open Access

    Regional and national variation in donor and recipient characteristics, transplant practice, and outcomes after liver transplantation (the IMPROVEMENT collaborative): a multicentre cohort study

    by Alfonso W. Avolio, Marco M. Pascale, Quirino Lai, Patrizia Burra, Umberto Cillo, Kristopher P. Croome, Martin De Santibanes, Hiroto Egawa, Mikel M. Gastaca, Zhiyong Guo, et al.

  • Challenges in obese liver transplant recipients

    by Sudhindran Surendran, Viju Kumar Bharathan, Christi Titus Varghese

    Purpose of review: The global obesity epidemic has significantly altered the epidemiology of chronic liver disease and liver transplantation, with metabolic dysfunction-associated steatohepatitis emerging as a rapidly increasing indication for liver transplantation worldwide. Obesity in liver transplantation candidates is frequently accompanied by sarcopenia, frailty, cardiovascular disease, and metabolic comorbidities, creating complex perioperative and long-term management challenges. This review summarizes contemporary evidence regarding assessment, pretransplant preparation, perioperative management, and long-term outcomes of obese liver transplant recipients, while highlighting evolving therapeutic strategies and unresolved clinical questions. Recent findings: Recent literature emphasizes that BMI alone inadequately characterizes obesity in cirrhosis, with body composition, sarcopenic obesity, visceral adiposity, and frailty emerging as important prognostic factors. Structured prehabilitation, lifestyle modification, incretin-based pharmacotherapy, and selective metabolic bariatric surgery have shown promising results in carefully selected patients. Although obesity increases perioperative complexity and postoperative complications, carefully selected obese recipients can achieve graft and patient survival comparable to nonobese recipients. Summary: Obesity should not be considered a contraindication to liver transplantation. Individualized recipient assessment, coordinated perioperative optimization, and long-term metabolic surveillance are essential to improve outcomes. Future research should refine obesity assessment beyond BMI and clarify the optimal integration of pharmacologic and surgical weight-loss strategies in liver transplantation candidates before and after transplantation.

  • Open Access

    Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study

    by Thierry Gustot, William Bernal, Javier Fernández, Eva Usón-Raposo, Juan Manuel Díaz, Alberto Queiroz Farias, Ashwin Rammohan, Sebastián Marciano, Alexander Kuo, Giovanni Perricone, et al.

  • Clinicopathological profile and outcomes of severe hepatitis A outbreak in India: A multicenter cross-sectional study

    by Arun Valsan, Gowri Priya Nair, Nipun Verma, Charles Panackel, K.T. Shenoy, Hasim Ahamed, Benoy Sebastian, Nandakumar R, Krishnadas Devadas, Priyanka Sivakumar, et al.

  • Impact of Pre-operative Single-dose Methylprednisolone on Outcomes After Major Hepatectomy in Adults: A Prospective, Randomised Controlled Trial

    by Muddada Vivekananda, Guhan Venkatakrishnan, Binoj S.P. Thankamony Amma, Christi T. Varghese, Krishnanunni Nair, Shweta Mallick, Ramachandran N. Menon, Unnikrishnan Gopalakrishnan, Dinesh Balakrishnan, Sudheer O. Vayoth, et al.

  • Open Access

    FXR agonist in post-liver transplantation patients: a randomized open-labeled study. [Protocol]

    by Anila K N, Saraswathy S Nair, Dinesh Balakrishnan`, Unnikrishnan G, Binoj S T, Ramachandran Narayana Menon, Christi Titus Varghese, Shweta Mallick, Krishnanunni Nair, Madhu Srinivasan Durairaj, et al.

    Liver diseases cause nearly 2 million deaths worldwide each year, with approximately 1 million deaths from cirrhosis complications and another 1 million from viral hepatitis and liver cancer, according to WHO estimates. Liver transplantation (LT) remains the primary curative option, boasting success rates of 85% in the first year and 75% at five years post-transplant. Despite high costs, LT is considered cost-effective, especially for younger patients with active work years remaining. However, post-transplant complications, particularly intrahepatic cholestasis, present notable challenges. This complication arises from factors such as ischemia-reperfusion injury, infections, immunological rejection, and surgical complications, all contributing to impaired bile flow and liver damage. Current medical therapies for post-LT cholestasis are limited, with ursodeoxycholic acid (UDCA) frequently used, despite questionable efficacy. Obeticholic acid (OCA), a potent Farnesoid X Receptor (FXR) agonist approved by the FDA for treating primary biliary cholangitis (PBC), has shown potential benefits in reducing elevated cholestatic liver enzymes. Given its significant effects on liver health, OCA may offer therapeutic value in managing post-transplant cholestasis and improving graft survival. This randomized controlled trial (RCT) aims to evaluate OCA’s efficacy compared to UDCA in reducing cholestatic injury and enhancing graft function post-LT. The primary outcomes will focus on a 15% reduction in alkaline phosphatase and gamma-glutamyl transferase levels at 3, 6, and 12 months from baseline one month. Secondary outcomes include molecular markers, biliary complications, graft rejection, quality of life, and cost-effectiveness. Results are anticipated to demonstrate that OCA could ameliorate cholestasis, improve graft survival, reduce post-transplant complications, and enhance quality of life, potentially setting a new standard in post-LT care if found beneficial.

  • Immediate Postoperative Care

    by Shweta Mallick, Krishnanunni Nair, S. Sudhindran

  • Open Access

    Predictive Value of Procalcitonin and C-reactive Protein for Mortality in Live Donor Liver Transplant Recipients

    by Saraswathy S, Johns Shaji Mathew, Anila Kn, Sreerenjini Sb, Georg Gutjahr, Shweta Mallick, Binoj St, Unnikrishnan G, Dinesh Balakrishnan, Sudhindran S

    Background: Accurate biomarkers are crucial for the early diagnosis of sepsis after liver transplantation. This study aimed to evaluate the diagnostic accuracy of procalcitonin (PCT) and C-reactive protein (CRP) in predicting bacterial infections and mortality following living donor liver transplantation (LDLT). Methodology: We prospectively analyzed all adult LDLT patients at a tertiary center between January 2021 and December 2022. CRP and PCT levels were measured on postoperative days (POD) one, three, five, and seven, and compared among patients without infections, those with bloodstream infections, and those with other infections (urinary, bronchoalveolar lavage, or drain). Multivariate logistic regression assessed the impact of PCT and CRP trends on short- and long-term mortality. Results: Among 216 LDLT patients, 122 (56%) were analyzed after applying exclusion criteria. In patients without infections, median CRP and PCT levels were elevated on days one (CRP: 19, interquartile range (IQR): 11-29; PCT: 3, IQR: 1-13) and three (CRP: 18, IQR: 7-30; PCT: 2, IQR: 1-9) but decreased by days five (CRP: 10, IQR: 5-16; PCT: 1, IQR: 0.2-3) and seven (CRP: 10, IQR: 3-17; PCT: 0.7, IQR: 0.3-3). No absolute values of CRP or PCT effectively diagnosed infections. Patients with a decreasing trend in CRP from POD three to five to seven had survival rates of 90%, 86%, and 85% at 30, 90, and 600 days, respectively; in contrast, those with an increasing CRP trend had lower survival rates of 78%, 71%, and 40%, respectively. Similarly, a decline in PCT was associated with 30-, 90-, and 600-day survival rates of 90%, 85%, and 84%, while increasing PCT correlated with significantly lower rates of 75%, 70%, and 30%, respectively. Conclusion: While the absolute values of CRP and PCT were not diagnostic for infection, an increase in these biomarkers from days three to five to seven predicted significantly higher short- and long-term mortality in LDLT recipients.

  • Reply: Tackling the learning curve for safe robotic living donor hepatectomy

    by Shweta Mallick, Krishnanunni Nair, Christi Titus Varghese, Sudhindran Surendran

  • Open Access

    Role of FXR Agonist in Cholestasis Following Live Donor Liver Transplantation: A Randomized Open-Label Trial

    by Anila Kn, Saraswathy S, Unnikrishnan G, Dinesh Balakrishnan, Shweta Mallick, Nafiya Muhammed Zackariah, Haritha Rajakrishnan, Rajana Gopinath, Sajitha Krishnan, Sudhindran S, et al.

    Background: Intrahepatic cholestasis is a frequent postoperative issue in living donor liver transplantation (LDLT), typically stemming from causes such as reperfusion-related damage, infections, biliovascular issues, or rejection. Prompt intervention is key to preserving graft viability and promoting long-term recovery. Objective: To evaluate the safety and efficacy of obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, versus ursodeoxycholic acid (UDCA) in post-liver transplant patients to ameliorate cholestatic injury and reduce biopsy-proven rejection. Methodology: In this randomized, open-label trial, adult LDLT recipients received OCA (5 mg/day) or UDCA (300 mg thrice daily) from postoperative day 3 for one year. The primary endpoint was ≥15% reduction in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) from one-month postoperative baseline assessed at three, six, and 12 months. Secondary outcomes included changes in relevant biochemical tests and molecular parameters like plasma bile acids, transforming growth factor-beta (TGF-β), cytokeratin-18 (CK-18), serum autotaxin, fibroblast growth factor-19 (FGF-19), and bile salt export pump (BSEP), as well as the incidence of rejection, early allograft dysfunction (EAD), biliary complications, mortality, adverse events, and quality of life (QoL). Results: In the interim analysis of 83 patients, more than a 15% reduction in ALP between six and 12 months was observed in a higher proportion of patients in the OCA group (43%) than in the UDCA group (21%) (p=0.036). More than a 15% reduction in GGT between one and three months was observed in 80% of patients in the OCA group compared to 62% in the UDCA group (p=0.062). Plasma bile acids were lower in the OCA group at one month (170 vs. 226 µmol/L; p=0.012). Low-density lipoprotein (LDL)-cholesterol was higher in the OCA group at three (OCA 121 vs UDCA 107, p=0.027) and six months (OCA 130 vs UDCA 117, p=0.043). UDCA therapy resulted in a significantly greater improvement in overall QoL, with higher gains in both total mean and domain scores compared to OCA. No differences were detected in rejection, biliary complications, mortality, or other secondary endpoints. Conclusion: OCA led to greater biochemical improvement, while better QoL was achieved with UDCA in LDLT recipients, with a comparable safety profile.